Cough suppressant abuse may lead to dispensing restrictions

08/31/2010 | Bloomberg

The FDA might review cough medications from Pfizer and Johnson & Johnson for possible dispensing restrictions, after the agency found an increased number of emergency department visits associated with misuse of dextromethorphan from 2004 to 2008. An FDA advisory panel is scheduled Sept. 14 to discuss whether the common cough suppressant should be a controlled substance.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA